Literature DB >> 15657375

Elevated serum interferon-gamma-inducible chemokine-10/CXC chemokine ligand-10 in autoimmune primary adrenal insufficiency and in vitro expression in human adrenal cells primary cultures after stimulation with proinflammatory cytokines.

Mario Rotondi1, Alberto Falorni, Annamaria De Bellis, Stefano Laureti, Pietro Ferruzzi, Paola Romagnani, Andrea Buonamano, Elena Lazzeri, Clara Crescioli, Massimo Mannelli, Fausto Santeusanio, Antonio Bellastella, Mario Serio.   

Abstract

Chemokines are a large family of cytokines involved in the pathogenesis of inflammatory and autoimmune diseases. Among CXC chemokines, CXC chemokine ligand 10 (CXCL10) has been identified to play an important role in several endocrinological autoimmune diseases, such as Hashimoto's thyroiditis, Graves' disease, and type 1 diabetes mellitus. Although the mechanisms leading to glandular autoimmune process may be at least in part shared by different endocrine organs, the role of CXCL10 in autoimmune adrenal insufficiency is unknown. The aim of this study was to evaluate the role of CXCL10 in Addison's disease (AD). Serum CXCL10 levels were assayed in 64 patients with clinically evident autoimmune AD, 20 patients with autoimmune subclinical AD, nine patients with nonautoimmune AD, and 48 healthy volunteers. Clinically evident and subclinical AD, but not nonautoimmune AD patients, showed a significant increase in serum CXCL10 levels compared with healthy subjects: 119.9 pg/ml (range, 39.8-427.6) and 124.0 pg/ml (range, 37.0-384.7) vs. 75.6 pg/ml (range, 22.4-164.0; P < 0.001 for both groups). Comparable serum CXCL10 levels were found between patients with an isolated form of AD and patients with other autoimmune conditions associated with AD, suggesting a specific influence of the adrenal autoimmune process in determining elevated CXCL10 concentrations in such patients. No relationship was found between serum CXCL10 levels and anti-21-hydroxylase or adrenal cortex autoantibody titers or between CXCL10 levels and duration of disease. The role of CXCL10 in the adrenal gland was also evaluated in vitro in human zona fasciculata cells (hZFC). CXCL10, although not basally detected in cultured hZFC, was strongly induced by interferon-gamma and synergistically increased by TNF-alpha addition. Hydrocortisone or ACTH alone had no effect on CXCL10 secretion in hZFC, but they both significantly inhibited cytokine-induced CXCL10 secretion. Taken together, these data suggest a potential role of hZFC, through the production of CXCL10, in regulating the recruitment of specific subsets of activated lymphocytes in autoimmune AD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15657375     DOI: 10.1210/jc.2004-1062

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  20 in total

1.  Simultaneous evaluation of the circulating levels of both Th1 and Th2 chemokines in patients with autoimmune Addison's disease.

Authors:  G Bellastella; M Rotondi; E Pane; S Costantini; C Colella; R Calemma; F Capone; A Falorni; G Castello; A A Sinisi; A Bizzarro; L Chiovato; A Bellastella; A De Bellis
Journal:  J Endocrinol Invest       Date:  2010-12-15       Impact factor: 4.256

2.  Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity.

Authors:  James P Strassner; Mehdi Rashighi; Maggi Ahmed Refat; Jillian M Richmond; John E Harris
Journal:  J Am Acad Dermatol       Date:  2017-03-01       Impact factor: 11.527

3.  Vitamin D and interferon-γ co-operate to increase the ACE-2 receptor expression in primary cultures of human thyroid cells.

Authors:  F Coperchini; A Greco; M Denegri; F A Ripepi; B Grillini; J Bertini; B Calì; L Villani; F Magri; L Croce; C Gaetano; C Cappelli; P Trimboli; L Chiovato; M Rotondi
Journal:  J Endocrinol Invest       Date:  2022-07-12       Impact factor: 5.467

4.  Biomarkers for type 1 diabetes.

Authors:  Sharad Purohit; Jin-Xiong She
Journal:  Int J Clin Exp Med       Date:  2008-02-29

5.  CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo.

Authors:  Mehdi Rashighi; Priti Agarwal; Jillian M Richmond; Tajie H Harris; Karen Dresser; Ming-Wan Su; Youwen Zhou; April Deng; Christopher A Hunter; Andrew D Luster; John E Harris
Journal:  Sci Transl Med       Date:  2014-02-12       Impact factor: 17.956

Review 6.  The potential role for infections in the pathogenesis of autoimmune Addison's disease.

Authors:  A Hellesen; E Bratland
Journal:  Clin Exp Immunol       Date:  2018-09-30       Impact factor: 4.330

7.  Expression of CXCR3 and its ligands CXCL9, -10 and -11 in paediatric opsoclonus-myoclonus syndrome.

Authors:  M R Pranzatelli; E D Tate; N R McGee; A L Travelstead; S J Verhulst; R M Ransohoff
Journal:  Clin Exp Immunol       Date:  2013-06       Impact factor: 4.330

8.  The effect of types I and III interferons on adrenocortical cells and its possible implications for autoimmune Addison's disease.

Authors:  A Hellesen; K Edvardsen; L Breivik; E S Husebye; E Bratland
Journal:  Clin Exp Immunol       Date:  2014-06       Impact factor: 4.330

Review 9.  Vitamin D receptor agonists target CXCL10: new therapeutic tools for resolution of inflammation.

Authors:  Sabino Scolletta; Marta Colletti; Luigi Di Luigi; Clara Crescioli
Journal:  Mediators Inflamm       Date:  2013-04-17       Impact factor: 4.711

10.  Modulation of ACE-2 mRNA by inflammatory cytokines in human thyroid cells: a pilot study.

Authors:  Francesca Coperchini; Gianluca Ricci; Laura Croce; Marco Denegri; Rubina Ruggiero; Laura Villani; Flavia Magri; Luca Chiovato; Mario Rotondi
Journal:  Endocrine       Date:  2021-07-05       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.